Disc Medicine (NASDAQ:IRON) Given New $88.00 Price Target at Wedbush

Disc Medicine (NASDAQ:IRON) had its price target cut by Wedbush from $110.00 to $88.00 in a research note published on Tuesday, Marketbeat reports. They currently have an outperform rating on the stock.

Several other research analysts also recently commented on the stock. Stifel Nicolaus assumed coverage on shares of Disc Medicine in a research note on Monday, November 3rd. They issued a “buy” rating and a $125.00 price target on the stock. TD Cowen restated a “buy” rating on shares of Disc Medicine in a research note on Friday, December 19th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research note on Wednesday, January 21st. Wells Fargo & Company boosted their price target on Disc Medicine from $91.00 to $109.00 and gave the company an “overweight” rating in a report on Tuesday, December 16th. Finally, BMO Capital Markets reduced their price objective on Disc Medicine from $120.00 to $100.00 and set an “outperform” rating on the stock in a report on Tuesday. Eleven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Disc Medicine has a consensus rating of “Moderate Buy” and a consensus target price of $104.82.

Disc Medicine Stock Performance

IRON stock opened at $65.57 on Tuesday. Disc Medicine has a twelve month low of $30.82 and a twelve month high of $99.50. The firm has a market cap of $2.48 billion, a price-to-earnings ratio of -12.26 and a beta of 0.88. The business’s fifty day simple moving average is $78.41 and its two-hundred day simple moving average is $75.28. The company has a quick ratio of 23.45, a current ratio of 23.45 and a debt-to-equity ratio of 0.05.

Insider Activity

In other Disc Medicine news, insider Pamela Stephenson sold 5,531 shares of the stock in a transaction on Tuesday, February 17th. The stock was sold at an average price of $62.86, for a total transaction of $347,678.66. Following the sale, the insider owned 80,998 shares of the company’s stock, valued at approximately $5,091,534.28. This trade represents a 6.39% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John D. Quisel sold 40,000 shares of Disc Medicine stock in a transaction on Thursday, December 11th. The shares were sold at an average price of $93.05, for a total value of $3,722,000.00. Following the completion of the transaction, the chief executive officer owned 171,828 shares in the company, valued at $15,988,595.40. This represents a 18.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 273,605 shares of company stock valued at $24,193,736. 3.64% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Disc Medicine

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Logos Global Management LP raised its holdings in Disc Medicine by 13.3% in the fourth quarter. Logos Global Management LP now owns 510,000 shares of the company’s stock worth $40,499,000 after purchasing an additional 60,000 shares in the last quarter. Burkehill Global Management LP bought a new stake in shares of Disc Medicine in the 4th quarter valued at about $3,970,000. Abel Hall LLC purchased a new position in shares of Disc Medicine in the 4th quarter worth approximately $353,000. Lazard Asset Management LLC bought a new position in shares of Disc Medicine during the 4th quarter worth approximately $4,610,000. Finally, Jain Global LLC purchased a new stake in Disc Medicine during the fourth quarter valued at approximately $581,000. Hedge funds and other institutional investors own 83.70% of the company’s stock.

More Disc Medicine News

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: Management announced it will pursue a traditional U.S. approval pathway for bitopertin after the FDA declined the new fast‑track route — provides a clear regulatory path rather than abandoning the program. Read More.
• Positive Sentiment: Several sell‑side analysts kept constructive ratings (outperform/overweight) despite trimming price targets, which can support buying interest from institutional holders. Read More. Read More. Read More.
• Neutral Sentiment: Company held an investor call/transcript covering the FDA Complete Response Letter and next steps; investors are parsing details on timing and additional data requests. Read More.
• Neutral Sentiment: Analyst and market commentary is mixed — some note increased near‑term regulatory risk while others emphasize remaining upside if APOLLO/other trials read out favorably. Read More.
• Neutral Sentiment: Reported short‑interest data is noisy/insignificant in the latest print, so part of today’s move appears driven by event trading and position rebalancing rather than a conventional short squeeze. (Company filings/market data)
• Negative Sentiment: Pomerantz LLP launched an investor investigation into Disc Medicine, introducing potential litigation risk and associated headline pressure. Read More.
• Negative Sentiment: Coverage reports the FDA rejection was accompanied by skepticism from key advisers, amplifying uncertainty about the data package and timelines for resubmission. That increases the odds of delays or additional data requirements. Read More.
• Negative Sentiment: Multiple firms cut price targets today — even where ratings stayed positive — reflecting a lower near‑term valuation baseline until regulatory clarity is restored. Read More.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.